Piper Jaffray Remains Bullish on Lam Research (LRCX) as Technology Inflections Continue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Notable Analyst Rating Changes 10/5: (TWTR) (FOLD) (JNPR) Upgraded; (SNI) (LRCX) (FEYE) Downgraded
October 5, 2015 10:24 AM EDTUPGRADES
Axiom Capital upgraded Twitter, Inc. (NYSE: TWTR) from Hold to Buy with a price target of $37.
Chardan Capital Markets upgraded Amicus Therapeutics (Nasdaq: FOLD) from Neutral to Buy with a... More
Pre-Open Stock Movers 10/05: (ONCE) (FOLD) (TWTR) Higher; (APP) (FEYE) (VRX) Lower (more...)
October 5, 2015 9:24 AM EDTSpark Therapeutics (NASDAQ: ONCE) 37.4% HIGHER; announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs). The pivotal trial met its primary endpoint (p = 0.001), demonstrating improvement of functional vision in the intervention group compared to the control group, as measured by the change in bilateral mobility testing between baseline and one year.
American Apparel, Inc. (NYSE: APP) 24% LOWER; files Chapter 11
AmicusTherapeutics... More
RBC Capital Downgrades Lam Research (LRCX) to Underperform
October 5, 2015 6:25 AM EDTRBC Capital downgraded Lam Research (NASDAQ: LRCX) from Sector Perform to Underperform with a price target of $52.00 (from $76.00).
Analyst Mahesh Sanganeria commented, "We estimate CY16 total capex will be down 13% yoy to $46B, driven by 38% decline in DRAM capex, 17% drop in NAND spending,... More
